MX2019012849A - Metodos de tratamiento con polipeptidos del dominio extracelular del cd80. - Google Patents

Metodos de tratamiento con polipeptidos del dominio extracelular del cd80.

Info

Publication number
MX2019012849A
MX2019012849A MX2019012849A MX2019012849A MX2019012849A MX 2019012849 A MX2019012849 A MX 2019012849A MX 2019012849 A MX2019012849 A MX 2019012849A MX 2019012849 A MX2019012849 A MX 2019012849A MX 2019012849 A MX2019012849 A MX 2019012849A
Authority
MX
Mexico
Prior art keywords
treatment
methods
extracellular domain
domain polypeptides
polypeptides
Prior art date
Application number
MX2019012849A
Other languages
English (en)
Inventor
Brennan Thomas
Sennino Barbara
D Barbee Susannah
Jeffry Ursula
Original Assignee
Five Prime Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Five Prime Therapeutics Inc filed Critical Five Prime Therapeutics Inc
Publication of MX2019012849A publication Critical patent/MX2019012849A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume, or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume, or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N15/14—Electro-optical investigation, e.g. flow cytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N15/01—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume, or surface-area of porous materials
    • G01N15/10—Investigating individual particles
    • G01N2015/1006—Investigating individual particles for cytology
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70532—B7 molecules, e.g. CD80, CD86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

La presente solicitud hace referencia al uso de polipéptidos del dominio extracelular (ECD) del CD80 (B7- 1) y moléculas de fusión de CD80-ECD y su uso en métodos para aumentar la cantidad de linfocitos T de memoria central o para el tratamiento del cáncer o para el uso en composiciones de vacunas contra el cáncer.
MX2019012849A 2017-04-28 2018-04-27 Metodos de tratamiento con polipeptidos del dominio extracelular del cd80. MX2019012849A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762491479P 2017-04-28 2017-04-28
PCT/US2018/029897 WO2018201014A1 (en) 2017-04-28 2018-04-27 Methods of treatment with cd80 extracellular domain polypeptides

Publications (1)

Publication Number Publication Date
MX2019012849A true MX2019012849A (es) 2019-11-28

Family

ID=62196719

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019012849A MX2019012849A (es) 2017-04-28 2018-04-27 Metodos de tratamiento con polipeptidos del dominio extracelular del cd80.

Country Status (11)

Country Link
US (1) US11789010B2 (es)
EP (1) EP3628070B1 (es)
JP (2) JP2020517913A (es)
KR (1) KR20190139216A (es)
CN (1) CN110546509A (es)
AU (1) AU2018258661A1 (es)
CA (1) CA3057866A1 (es)
EA (1) EA201992586A1 (es)
ES (1) ES2899616T3 (es)
MX (1) MX2019012849A (es)
WO (1) WO2018201014A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20181300A1 (es) 2015-11-02 2018-08-09 Five Prime Therapeutics Inc Polipeptidos del dominio extracelular de cd80 y su uso en el tratamiento del cancer
JP2020517913A (ja) 2017-04-28 2020-06-18 ファイブ プライム セラピューティクス， インコーポレイテッド Ｃｄ８０細胞外ドメインポリペプチドによる治療方法
CN111148996A (zh) * 2017-07-28 2020-05-12 百时美施贵宝公司 用于检查点抑制剂的预测性外周血生物标志物
JP2021535083A (ja) * 2018-08-29 2021-12-16 ファイブ プライム セラピューティクス， インコーポレイテッド Ｃｄ８０細胞外ドメインｆｃ融合タンパク質投与レジメン
US20220348657A1 (en) * 2019-04-18 2022-11-03 Five Prime Therapeutics, Inc. Bioassay for t-cell co-stimulatory proteins containing fc domains
EP4054721A1 (en) * 2019-11-04 2022-09-14 Five Prime Therapeutics, Inc. Cd80 extracellular domain fc fusion protein dosing regimens
TWI820361B (zh) * 2019-11-27 2023-11-01 南韓商Ｇｉ醫諾微新股份有限公司 包含含有il-2蛋白與cd80蛋白之融合蛋白及免疫檢查點抑制劑的用於治療癌症的藥學組成物
EP4110802A1 (en) * 2020-02-26 2023-01-04 Five Prime Therapeutics, Inc. Cd80 extracellular domain fc fusion protein therapy
WO2021238904A1 (zh) * 2020-05-25 2021-12-02 北京比洋生物技术有限公司 Fc-CD80融合蛋白和其缀合物以及它们的用途

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7070776B1 (en) 1990-03-26 2006-07-04 Bristol-Myers Squibb Company Methods for blocking binding of CD28 receptor to B7
US6641809B1 (en) 1990-03-26 2003-11-04 Bristol-Myers Squibb Company Method of regulating cellular processes mediated by B7 and CD28
US6071716A (en) 1990-10-01 2000-06-06 Dana-Farber Cancer Institute DNA encoding, B7, a new member of the IG superfamily with unique expression on activated and neoplastic B cells
US6887471B1 (en) 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
US6130316A (en) 1993-07-26 2000-10-10 Dana Farber Cancer Institute Fusion proteins of novel CTLA4/CD28 ligands and uses therefore
US6824779B1 (en) 1993-07-26 2004-11-30 Dana-Farber Cancer Institute, Inc. Methods for inhibiting the interaction of B7-2 with its natural ligand
US5858776A (en) 1993-11-03 1999-01-12 Repligen Corporation Tumor cells with increased immunogenicity and uses therefor
US6218510B1 (en) 1994-03-02 2001-04-17 Brigham & Woman's Hospital B7-1 and B7-2 polypeptides
EP1025856A3 (en) 1994-03-08 2002-10-16 Dana-Farber Cancer Institute Methods for modulating T Cell unresponsiveness
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US20020147326A1 (en) 1996-06-14 2002-10-10 Smithkline Beecham Corporation Hexameric fusion proteins and uses therefor
US6491925B2 (en) 1996-08-15 2002-12-10 Emory University Compositions and methods for cancer prophylaxis and/or treatment
EP0988321A2 (en) 1997-06-20 2000-03-29 Innogenetics N.V. B7-binding molecules for treating immune diseases
WO2000025803A1 (fr) 1998-10-30 2000-05-11 Takeda Chemical Industries, Ltd. Preparations contenant une proteine betacelluline
US7011833B1 (en) 1999-05-06 2006-03-14 Genetics Institute, Inc. Enhancing immune responses with B7-1 or B7-2 in the absence of a crosslinking agent
US6429303B1 (en) 1999-09-03 2002-08-06 Curagen Corporation Nucleic acids encoding members of the human B lymphocyte activation antigen B7 family and methods of using the same
US7064111B1 (en) 1999-10-05 2006-06-20 Georgetown University Use of soluble costimulatory factor for tumor immuno-gene therapy
US7183376B2 (en) 2000-06-23 2007-02-27 Maxygen, Inc. Variant B7 co-stimulatory molecules
AU2002311787A1 (en) 2001-03-28 2002-10-15 Zycos Inc. Translational profiling
EP1497426A2 (en) 2001-06-22 2005-01-19 Maxygen, Inc. Co-stimulatory molecules
AU2002346373A1 (en) 2001-11-09 2003-05-19 Idec Pharmaceuticals Corporation Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
ATE469888T1 (de) 2003-05-22 2010-06-15 Abbott Lab Indazol-, benzisoxazol- und benzisothiazol- kinaseinhibitoren
US7307064B2 (en) 2003-08-04 2007-12-11 Bristol-Myers Squibb Company Methods for treating cardiovascular disease using a soluble CTLA4 molecule
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
EP2366717A3 (en) 2004-10-29 2011-12-14 University of Southern California Combination Cancer Immunotherapy with Co-Stimulatory Molecules
DK1866339T3 (da) 2005-03-25 2013-09-02 Gitr Inc GTR-bindende molekyler og anvendelser heraf
CA2607147C (en) 2005-05-09 2018-07-17 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
EP1879573B1 (en) 2005-05-10 2012-12-19 Incyte Corporation Modulators of indoleamine 2,3-dioxygenase and methods of using the same
WO2007014123A2 (en) 2005-07-22 2007-02-01 Five Prime Therapeutics, Inc. Compositions and methods of treating disease with fgfr fusion proteins
CA2634198C (en) 2005-12-20 2014-06-03 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
AU2007241023B2 (en) 2006-03-30 2013-11-28 University Of California Methods and compositions for localized secretion of anti-CTLA-4 antibodies
CN101528926A (zh) * 2006-08-18 2009-09-09 肿瘤疗法科学股份有限公司 过表达reg4或kiaa0101的癌症的治疗或预防
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
JP5319532B2 (ja) 2006-09-19 2013-10-16 インサイト・コーポレイション インドールアミン２，３−ジオキシゲナーゼのモジュレーターとしてのｎ−ヒドロキシアミジノヘテロサイクル
WO2008037080A1 (en) 2006-09-29 2008-04-03 Universite De Montreal Methods and compositions for immune response modulation and uses thereof
BRPI0809386A2 (pt) 2007-03-28 2014-09-09 Biogen Idec Inc Modulação de micro ambiente de tumor
EP2139922A1 (en) 2007-03-28 2010-01-06 Biogen Idec, Inc. Treatment of hodgkins lymphoma
HUE038506T2 (hu) 2007-03-30 2018-10-29 Memorial Sloan Kettering Cancer Center Kostimuláló ligand konstitutív expressziója adoptív módon átvitt T-limfocitákon
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
CN104945508B (zh) 2007-06-18 2019-02-22 默沙东有限责任公司 针对人程序性死亡受体pd-1的抗体
CA2693677C (en) 2007-07-12 2018-02-13 Tolerx, Inc. Combination therapies employing gitr binding molecules
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
PT2222697E (pt) * 2007-11-01 2013-02-15 Perseid Therapeutics Llc Polipeptídeos imunossupressores e ácidos nucleicos
JP5583592B2 (ja) 2007-11-30 2014-09-03 ニューリンク ジェネティクス コーポレイション Ｉｄｏ阻害剤
DK2234620T3 (en) 2008-01-03 2016-06-06 Université D'aix-Marseille Triple therapy used for treatment of an hiv-infected patient
US20100285039A1 (en) 2008-01-03 2010-11-11 The Johns Hopkins University B7-H1 (CD274) Antagonists Induce Apoptosis of Tumor Cells
HUE028958T2 (en) 2008-02-08 2017-01-30 Medimmune Llc Anti-IFNAR1 antibodies with reduced Fc ligand affinity
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
BRPI0917891A2 (pt) 2008-08-25 2015-11-24 Amplimmune Inc antagonistas de pd-1 e métodos de utilização dos mesmos
EP2350129B1 (en) 2008-08-25 2015-06-10 Amplimmune, Inc. Compositions of pd-1 antagonists and methods of use
CN102574924A (zh) 2009-09-03 2012-07-11 先灵公司 抗-gitr抗体
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
JP5998060B2 (ja) 2010-03-04 2016-09-28 マクロジェニクス，インコーポレーテッド Ｂ７−ｈ３と反応性のある抗体、その免疫学的に活性なフラグメントおよびその使用
SG10201506906VA (en) * 2010-09-09 2015-10-29 Pfizer 4-1bb binding molecules
WO2012130831A1 (en) 2011-03-29 2012-10-04 Roche Glycart Ag Antibody fc variants
NO2694640T3 (es) 2011-04-15 2018-03-17
BR112013026199A2 (pt) * 2011-04-15 2017-11-07 Compugen Ltd polipeptídeo isolado, proteína de fusão, sequência de ácidos nucleicos, vetor de expressão ou um vírus, célula recombinante, método de produção de um polipeptídeo com ectodomínio solúvel lsr, ou seu fragmento ou proteína de fusão, composição farmacêutica, uso de um anticorpo monoclonal ou policlonal ou um seu fragmento de ligação ao antígeno, uso do anticorpo ou do fragmento de ligação ao antígeno, uso de qualquer um de um polipeptídeo isolado, método de regulação por cima de citocinas, indução da expansão de células t, promoção da imunidade de células t específica antigênica e promoção da ativação das células t cd4+ e/ou cd8+ em um sujeito, método para potenciação de uma resposta imune secundária a um antígeno em um paciente, método de uso de pelo menos um de: um polipeptídeo isolado, método para tratamento ou prevenção de uma condição relacionada com o sistema imune, método para tratamento ou prevenção de uma doença infecciosa, método para diagnóstico de uma doença em um sujeito, método de produção de um polipeptídeo com ectodomínio solúvel tmem25, vsig10, ly6g6f, ou seu fragmento ou proteína de fusão, anticorpo monoclonal ou policlonal ou um seu fragmento de ligação ao antígeno, método de imunoterapia em um paciente e método para combinação de vacinação terapêutica com um antígeno em conjunto com a administração de qualquer um de um polipeptídeo
CN103796681B (zh) 2011-06-30 2018-07-20 建新公司 T细胞活化的抑制剂
JP6240600B2 (ja) 2011-07-24 2017-11-29 キュアテク リミテッド ヒト化免疫モノクローナル抗体の変異体
WO2013019906A1 (en) 2011-08-01 2013-02-07 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
US8956619B2 (en) * 2011-10-25 2015-02-17 University Of Maryland, Baltimore County Soluble CD80 as a therapeutic to reverse immune supression in cancer patients
EP2794653B1 (en) * 2011-12-23 2019-03-13 Pfizer Inc Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
WO2013116686A1 (en) 2012-02-02 2013-08-08 Massachusetts Institute Of Technology Methods and products related to targeted cancer therapy
EP2809345A4 (en) 2012-02-03 2015-11-25 Univ Emory IMMUNOSTIMULATING COMPOSITIONS, PARTICLES THEREFOR, AND USES THEREFOR
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
EP2970436B1 (en) 2013-03-15 2018-09-05 AbbVie Biotherapeutics Inc. Fc variants
PL2972373T3 (pl) 2013-03-15 2020-03-31 F. Hoffmann-La Roche Ag Biomarkery i sposoby leczenia stanów związanych z PD-1 i PD-L1
EP2969009B1 (en) 2013-03-15 2018-11-28 Pyranose Biotherapeutics, Inc. Modified fc fusion proteins
EP2839842A1 (en) * 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
TW201605896A (zh) 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
US10259875B2 (en) 2013-10-01 2019-04-16 Mayo Foundation For Medical Education And Research Methods for treating cancer in patients with elevated levels of BIM
WO2015100219A1 (en) 2013-12-23 2015-07-02 Oncomed Pharmaceuticals, Inc. Immunotherapy with binding agents
JP6666267B2 (ja) * 2014-05-29 2020-03-13 メディミューン，エルエルシー Ｏｘ４０ｌ融合タンパク質およびその使用
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
US20160009805A1 (en) 2014-07-11 2016-01-14 Genentech, Inc. Anti-pd-l1 antibodies and diagnostic uses thereof
JP2017534577A (ja) 2014-09-15 2017-11-24 ジェネンテック， インコーポレイテッド Ｐｄ−１軸結合拮抗薬及びｉｌ−１７結合拮抗薬を使用したがんの治療方法
IL254335B2 (en) 2015-03-16 2023-04-01 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Isolated peptides derived from the dimerization regions of b7
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
PT3283508T (pt) 2015-04-17 2021-06-21 Alpine Immune Sciences Inc Proteínas imuno modulatórias com afinidades afináveis
KR20180118249A (ko) 2015-04-30 2018-10-30 싸이오서스 테라퓨틱스 엘티디. B7 단백질을 암호화하는 종양세포붕괴 아데노바이러스
GEP20227419B (en) 2015-07-30 2022-10-10 Macrogenics Inc Pd-1-binding molecules and methods of use thereof
CN106397592A (zh) 2015-07-31 2017-02-15 苏州康宁杰瑞生物科技有限公司 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白
WO2017042814A1 (en) 2015-09-10 2017-03-16 Yeda Research And Development Co. Ltd. Use of perforin positive immature dendritic cells in disease treatment
CN108513576A (zh) 2015-09-14 2018-09-07 高山免疫科学股份有限公司 可调变体免疫球蛋白超家族结构域和工程改造的细胞治疗
PE20181300A1 (es) 2015-11-02 2018-08-09 Five Prime Therapeutics Inc Polipeptidos del dominio extracelular de cd80 y su uso en el tratamiento del cancer
KR20180108590A (ko) 2015-12-17 2018-10-04 싸이오서스 테라퓨틱스 엘티디. 항-tcr-복합체 항체 또는 단편을 암호화하는 바이러스
CA3014001A1 (en) 2016-02-25 2017-08-31 Cell Medica Switzerland Ag Binding members to pd-l1
KR20180132663A (ko) 2016-03-02 2018-12-12 큐 바이오파마, 인크. T-세포 조절 다량체 폴리펩타이드 및 이의 사용 방법
EP3423087B1 (en) 2016-03-04 2023-11-15 IO Biotech APS Combination therapy against cancer
JP2019521643A (ja) 2016-04-15 2019-08-08 アルパイン イミューン サイエンシズ インコーポレイテッド Ｃｄ８０バリアント免疫調節タンパク質およびその使用
WO2017181148A2 (en) 2016-04-15 2017-10-19 Alpine Immune Sciences, Inc. Icos ligand variant immunomodulatory proteins and uses thereof
AU2017268399B2 (en) 2016-05-18 2023-01-12 Modernatx, Inc. mRNA combination therapy for the treatment of cancer
CN109475628A (zh) 2016-05-18 2019-03-15 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
US10906957B2 (en) 2016-09-27 2021-02-02 Epicentrx, Inc. Immunomodulatory fusion proteins
SG11201903407XA (en) 2016-10-20 2019-05-30 Alpine Immune Sciences Inc Secretable variant immunomodulatory proteins and engineered cell therapy
JP2020517913A (ja) 2017-04-28 2020-06-18 ファイブ プライム セラピューティクス， インコーポレイテッド Ｃｄ８０細胞外ドメインポリペプチドによる治療方法
JP2021535083A (ja) 2018-08-29 2021-12-16 ファイブ プライム セラピューティクス， インコーポレイテッド Ｃｄ８０細胞外ドメインｆｃ融合タンパク質投与レジメン
KR20210130706A (ko) 2019-02-22 2021-11-01 파이브 프라임 테라퓨틱스, 인크. PD-L1 음성 종양을 치료하기 위한 CD80 세포외 도메인 Fc 융합 단백질
WO2020227062A1 (en) 2019-05-03 2020-11-12 Five Prime Therapeutics, Inc. Pharmaceutical formulations containing cd80 extracellular domain-fc fusion proteins

Also Published As

Publication number Publication date
AU2018258661A1 (en) 2019-10-17
EP3628070A1 (en) 2020-04-01
CA3057866A1 (en) 2018-11-01
EA201992586A1 (ru) 2020-03-03
US11789010B2 (en) 2023-10-17
WO2018201014A1 (en) 2018-11-01
EP3628070B1 (en) 2021-09-08
JP2020517913A (ja) 2020-06-18
KR20190139216A (ko) 2019-12-17
JP2021095417A (ja) 2021-06-24
US20200182858A1 (en) 2020-06-11
ES2899616T3 (es) 2022-03-14
CN110546509A (zh) 2019-12-06

Similar Documents

Publication Publication Date Title
MX2019012849A (es) Metodos de tratamiento con polipeptidos del dominio extracelular del cd80.
PH12018500933A1 (en) Cd80 extracellular domain polypeptides and their use in cancer treatment
PH12018502429A1 (en) Antibody molecules for cancer treatment
PH12018502118A1 (en) Chimeric receptors to flt3 and methods of use thereof
PH12017500803A1 (en) Anti-pd-1 antibodies
MX2020005634A (es) Composiciones y metodos para mejorar los linfocitos infiltrantes de tumor para terapia celular adoptiva.
EA202090931A2 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
MX2020007266A (es) Moleculas del receptor quimerico de engullido y metodos de uso.
CA2956871C (en) Compounds active towards bromodomains
NZ743124A (en) Antibodies targeting fc receptor-like 5 and methods of use
SG10201806108TA (en) Binding proteins and methods of use thereof
MX2019013670A (es) Formulaciones de anticuerpos y proteinas.
CL2016001840A1 (es) Compuestos derivados de pirimidinas fusionadas como inhibidores del complejo p97; composicion farmaceutica y uso en el tratamiento del cancer.
PH12017500494A1 (en) Methyl-and trifluoromethyl-substituted pyrrolopyridine modulators of rorc2 and methods of use thereof
PH12019502036A1 (en) Peptides and methods for the treatment of diabetes
MX2018013742A (es) Formas cristalinas de crisaborol en forma libre, metodo de preparacion y uso de las mismas.
GB2540110A (en) Corneal inlay delivery devices and methods
MX2017006026A (es) Apilimod para uso en el tratamiento de cancer colorrectal.
AU2016356504A8 (en) 5-hydroxytryptamine 1B receptor-stimulating agent for enhancing in vivo engraftment potential
PH12018502139A1 (en) Phosphaplatin liquid formulations
MX2018015560A (es) Composicion cosmetica anti-signos, uso de la composicion, metodo de tratamiento anti-signos y dispositivo de aplicacion.
MX2018003313A (es) Celulas asesinas naturales modificadas con propiedades anti-fuctacticas y sus usos.
MX2017015738A (es) Metodo de prueba para ingredientes especificos en composiciones cosmeticas antitranspirantes y humectantes.
PH12017502208B1 (en) Testing method for specific ingredients in antiperspirant and humectant cosmetic compositions
NZ744131A (en) Tumor-infiltrating lymphocytes for adoptive cell therapy